The use of synthetic oligonucleotides as protein inhibitors and anticode drugs in cancer therapy: accomplishments and limitations.
The function of gene products can be altered at many levels, including the mutation of gene sequence and the change in steady state levels of mRNA and/or protein by various mechanisms. The cumulative malfunction of specific gene products underlies many pathological conditions such as the multi-step and multi-cause acquisition of cancer. Here we discuss two oligonucleotide-based strategies in which these compounds target defective gene products acting either as antiprotein or anticode agents. The SELEX technique (systematic evolution of ligands by exponential enrichment) is an antiprotein approach in which nuclease-resistant DNA or RNA aptamers are selected by their ability to bind their protein targets with high affinity and specificity of the same range as antibodies. Such inhibitors were previously evolved against a great variety of targets, including receptors, growth factors and adhesion molecules implicated in the genesis of some kinds of cancer. Moreover, some results have already been obtained in animal models. The antigene technology interferes with earlier steps in the information flow leading from gene to protein. In this approach selective gene silencing is provided by the formation of stable and specific complexes between triplex forming molecules and their DNA targets. The feasibility of this strategy as well as a molecular mechanism for the action of antigene oligonucleotides has been demonstrated in cellular systems and in vivo. The use of oligonucleotide drugs (of either the antiprotein or the anticode type) as a viable approach to cancer therapy is limited by some common problems that will be discussed.
Faria
Marcella
M
Department of Biochemistry, Instituto de Química, Universidade de São Paulo, São Paulo, S. P. 05513-970, Caixa Postal 26077, Brazil. henning@iq.usp.br
Ulrich
Henning
H
D000818:Animals; D004273:DNA, Neoplasm / Q000187:drug effects; D016503:Drug Delivery Systems / Q000379:methods*; D005815:Genetic Code / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009841:Oligonucleotides / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use*; D014176:Protein Biosynthesis; D011500:Protein Synthesis Inhibitors / Q000138:chemical synthesis* / Q000627:therapeutic use*; D011506:Proteins / Q000037:antagonists & inhibitors*; D012334:RNA, Neoplasm / Q000187:drug effects
D004273:DNA, Neoplasm; D009841:Oligonucleotides; D011500:Protein Synthesis Inhibitors; D011506:Proteins; D012334:RNA, Neoplasm